| Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer F Posch, K Silina, S Leibl, A Mündlein, H Moch, A Siebenhüner, ... Oncoimmunology 7 (2), e1378844, 2018 | 303 | 2018 |
| The width of resection margins influences local recurrence in soft tissue sarcoma patients V Kainhofer, MA Smolle, J Szkandera, B Liegl-Atzwanger, W Maurer-Ertl, ... European Journal of Surgical Oncology (EJSO) 42 (6), 899-906, 2016 | 115 | 2016 |
| C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study JM Riedl, DA Barth, WM Brueckl, G Zeitler, V Foris, S Mollnar, M Stotz, ... Cancers 12 (8), 2319, 2020 | 86 | 2020 |
| Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis JM Riedl, F Posch, L Horvath, A Gantschnigg, F Renneberg, ... European Journal of Cancer 151, 3-13, 2021 | 50 | 2021 |
| The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of … JM Riedl, F Posch, G Prager, W Eisterer, L Oehler, T Sliwa, K Wilthoner, ... Therapeutic advances in medical oncology 12, 1758835919900872, 2020 | 50 | 2020 |
| Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer SO Perakis, S Weber, Q Zhou, R Graf, S Hojas, JM Riedl, A Gerger, ... Esmo Open 5 (5), e000872, 2020 | 36 | 2020 |
| Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting JM Riedl, F Posch, F Moik, A Bezan, J Szkandera, MA Smolle, ... Oncotarget 8 (56), 96048, 2017 | 36 | 2017 |
| Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer Q Zhou, SO Perakis, P Ulz, S Mohan, JM Riedl, E Talakic, S Lax, M Tötsch, ... Genome medicine 12, 1-17, 2020 | 31 | 2020 |
| Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7: e1378844 F Posch, K Silina, S Leibl, A Mündlein, H Moch, A Siebenhüner, ... | 29 | 2018 |
| The AST/ALT ratio is an independent prognostic marker for disease-free survival in stage II and III colorectal carcinoma L Scheipner, MA Smolle, D Barth, F Posch, M Stotz, M Pichler, H Stoeger, ... Anticancer Research 41 (1), 429-436, 2021 | 26 | 2021 |
| Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis F Moik, JM Riedl, T Winder, A Terbuch, CH Rossmann, J Szkandera, ... Scientific Reports 9 (1), 5548, 2019 | 24 | 2019 |
| T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study MA Smolle, L Herbsthofer, B Granegger, M Goda, I Brcic, M Bergovec, ... British journal of cancer 125 (5), 717-724, 2021 | 21 | 2021 |
| External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients DA Barth, C Brenner, JM Riedl, F Prinz, EV Klocker, K Schlick, P Kornprat, ... Cancer Medicine 9 (15), 5473-5479, 2020 | 21 | 2020 |
| Decreased activity of circulating butyrylcholinesterase in blood is an independent prognostic marker in pancreatic cancer patients EV Klocker, DA Barth, JM Riedl, F Prinz, J Szkandera, K Schlick, ... Cancers 12 (5), 1154, 2020 | 21 | 2020 |
| Surgery for metachronous metastasis of soft tissue sarcoma–A magnitude of benefit analysis using propensity score methods MA Smolle, VM van Praag, F Posch, M Bergovec, L Leitner, ... European Journal of Surgical Oncology 45 (2), 242-248, 2019 | 21 | 2019 |
| Cancer stem cell gene variants in CD44 predict outcome in stage II and stage III colon cancer patients M Stotz, SA Herzog, M Pichler, M Smolle, J Riedl, C Rossmann, A Bezan, ... Anticancer Research 37 (4), 2011-2018, 2017 | 21 | 2017 |
| Patterns of peripheral blood B-cell subtypes are associated with treatment response in patients treated with immune checkpoint inhibitors: a prospective longitudinal pan-cancer … DA Barth, S Stanzer, JA Spiegelberg, T Bauernhofer, G Absenger, ... Frontiers in immunology 13, 840207, 2022 | 20 | 2022 |
| Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational … D Bianconi, M Herac, F Posch, M Schmeidl, M Unseld, M Kieler, ... Therapeutic Advances in Medical Oncology 12, 1758835920928635, 2020 | 19 | 2020 |
| Individualizing follow-up strategies in high-grade soft tissue sarcoma with flexible parametric competing risk regression models MA Smolle, M van de Sande, D Callegaro, J Wunder, A Hayes, L Leitner, ... Cancers 12 (1), 47, 2019 | 19 | 2019 |
| Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study JM Riedl, F Posch, A Bezan, J Szkandera, MA Smolle, T Winder, ... BMC cancer 17, 1-8, 2017 | 18 | 2017 |
Martin PichlerMedical University of GrazEmail yang diverifikasi di medunigraz.at